GlassScriptPhysician profile
Tesfaye Telila
NPI 1699054775
$1,436.34
in general payments reported to CMS, 2019-2025
22 companies · $335 in 2025
The $335 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $537 · 2020: $12.95 · 2021: $139 · 2022: $187 · 2023: $144 · 2024: $80.92 · 2025: $335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $559.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $323.64 | 2019 | |
| Medtronic Vascular, INC. | $146.67 | 2019 | |
| Abbott Laboratories | $127.12 | 2021-2025 | Cardiomems |
| Shockwave Medical, INC | $103.07 | 2025 | |
| Angiodynamics, INC. | $90.22 | 2020-2025 | Alphavac |
| Boston Scientific Corporation | $84.62 | 2019-2025 | General - Vascular Access |
| Janssen Pharmaceuticals, INC | $84.28 | 2019-2023 | Xarelto |
| Inari Medical, INC. | $64.62 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.48 | 2022-2023 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $43.86 | 2019-2024 | Lifevest |
| Becton, Dickinson and Company | $42.37 | 2025 | Hemosphere |
| Chiesi USA, INC. | $38.50 | 2024-2025 | Kengreal |
| Philips North America LLC | $38.04 | 2021 | |
| Heartflow, INC. | $34.15 | 2022-2023 | Ffrct |
| Amgen INC. | $26.12 | 2021-2023 | Repatha |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $22.44 | 2022 | |
| Acist Medical Systems, INC. | $21.03 | 2024 | |
| Cardiovascular Systems INC. | $18.85 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $18.73 | 2024 | Eliquis |
| Pfizer INC. | $17.99 | 2024 | |
| Inspire Medical Systems, INC. | $17.92 | 2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $11.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tesfaye Telila listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.